Protocols - Hemorio

More documents

Recommendations

Info

224 NOTES ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________
224 NOTES ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________
Page 2 and 3:
PROTOCOLS INSTITUTE OF HAEMATOLOGY
Page 4 and 5:
COORDINATION AND REVISION Clarisse
Page 6 and 7:
SUMMARY: PART I - CLINICAL PROTOCOL
Page 8 and 9:
1.INICIAL CLINICAL EVALUATION SICKL
Page 10 and 11:
TREATMENTO AND IN ADULTS AT ANY AGE
Page 12 and 13:
SPLENECTOMY - INDICATIONS: (1) CHIL
Page 14 and 15:
OUTPATIENT TREATMENT: It is based o
Page 16 and 17:
ASPIRIN AND NSAID PARACETAMOL OPIOI
Page 18 and 19:
CONDUCTION: - Hospitalization - Com
Page 20 and 21:
ONE, TWO-DIMENSIONAL DOPPLER ECHOCA
Page 22 and 23:
Hemianopsia Homonymous deficit of v
Page 24 and 25:
TREATMENT OF CONVULSIVE EPISODES -
Page 26 and 27:
INITIAL ATTENDANCE TO PREGNANT WOME
Page 28 and 29:
- It may occurs acute thoracic synd
Page 30 and 31:
3 Diet with potassium restriction 4
Page 32 and 33:
MICROALBUMINURIA Screening Patients
Page 34 and 35:
RECURRENCE OF PRIAPISM: - Pain Trea
Page 36 and 37:
SPECIAL CARES DEFERASIROX - The use
Page 38 and 39:
TREATAMENT: DRUG Hydroxiurea (hard
Page 40 and 41:
MAJOR AND INTERMIDIATE THALASSEMIA
Page 42 and 43:
HEREDIRATY SPHEROCYTOSIS CLINICAL E
Page 44 and 45:
G6PD DEFICIENCY INITIAL EVALUATION
Page 46 and 47:
LABS EXAMS TO DIAGNOSE APLASTIC ANE
Page 48 and 49:
SELFIMMUNE HEMOLYTIC ANEMIA CONCEPT
Page 50 and 51:
2. Splenectomy: Vaccinate 14 days b
Page 52 and 53:
IMMUNE THROMBOCYTOPENIC PURPURA LAB
Page 54 and 55:
THROMBOTIC THROMBOCYTOPENIC PURPURA
Page 56 and 57:
HEMORRHAGIC SYNDROME INTRODUCTION H
Page 58 and 59:
MULTIDISCIPLINARY FOLLOW-UP OF HEMO
Page 60 and 61:
LYOPHILIZED CONCENTRATES: They are
Page 62 and 63:
TABLE 2: REPLACEMENT THERAPY TO PER
Page 64 and 65:
CONDUCTION IN CONFIRMED INTRACRANIA
Page 66 and 67:
Severe CET with neurological change
Page 68 and 69:
PHARMACOKINETICS OF CLOTTING FACTOR
Page 70 and 71:
INHIBITORS CLASSIFICATION The inhib
Page 72 and 73:
- Extended surgeries require increa
Page 74 and 75:
CLINICAL DIAGNOSIS: According to In
Page 76 and 77:
DDAVP TEST The “test dose” must
Page 78 and 79:
TREATMENT OF BLEEDING SITUATIONS SI
Page 80 and 81:
TABLE 6 - REPLACEMENT THERAPY IN LE
Page 82 and 83:
• Primary prophylaxis: controvers
Page 84 and 85:
CLINICAL AND LABORATORIAL FOLLOW-UP
Page 86 and 87:
MYELODISPLASIC SYNDROME LABORATORIA
Page 88 and 89:
If EPO < 500 mU/ml : EPO (8000U 3x/
Page 90 and 91:
ACUTE MYELOID LEUKEMIA LABORATORIAL
Page 92 and 93:
LMA LMA M3 - non-M3 LMA Protocol LM
Page 94 and 95:
Key: Volunteer to aggressive treatm
Page 96 and 97:
Acute Promyelocytic Leukemia Transf
Page 98 and 99:
BMP LMA IN CHILDREN AND TEENAGERS
Page 100 and 101:
Ara-c dose reduction by age: Age in
Page 102 and 103:
ATRA RECOMMENDATION: ATRA is starte
Page 104 and 105:
- venous hydration - leukapheresis
Page 106 and 107:
POLYCYTHEMIA VERA LABORATORIAL TEST
Page 108 and 109:
TREATMENT - 2nd LINE - Indicated fo
Page 110 and 111:
ACUTE LYMPHOID LEUKEMIA LABORATORIA
Page 112 and 113:
RE-INDUCTION Phase I (weeks 1-4) -
Page 114 and 115:
Cycles 2, 4, 6, 8 - Methotrexate 20
Page 116 and 117:
PHASE 2 Infusion CPM in 1 hour 1000
Page 118 and 119:
CURATIVE RADIOTHERAPY of CNS < 1 ye
Page 120 and 121:
CHRONIC LYMPHOCYTIC LEUKEMIA LABORA
Page 122 and 123:
fludarabine 25 mg/m VENOUS 2 D1-D3
Page 124 and 125:
TRICHOLEUKEMIA LABORATORIAL TESTS -
Page 126 and 127:
- age >45 years old - leukocytosis
Page 128 and 129:
- Leukemia / T-Cell Lymphoma in Adu
Page 130 and 131:
INDICATIONS FOR THE TREATMENT: Symp
Page 132 and 133:
1 st line Chemotherapy R- CHOP (21
Page 134 and 135:
CODOX- M/IVAC Cycles 1 and 3 Cyclop
Page 136 and 137:
BLOCK A DEXA VO/IV 10 mg /m2 in 3 d
Page 138 and 139:
- Surgical treatment is only indica
Page 140 and 141:
LEUKEMIA / T-CELLS LYMPHOMA OF THE
Page 142 and 143:
HN2 or PUVA (similar to the located
Page 144 and 145:
MULTIPLE MYELOMA LABORATORIAL TESTS
Page 146 and 147:
RESPONSE CRITERIA Full Response Abs
Page 148 and 149:
WALDENSTRON MACROGLOBULINEMIA LABOR
Page 150 and 151:
− If HLA-identical related donor
Page 152 and 153:
TREATMENT PROTOCOL - ACUTE MYELOID
Page 154 and 155:
TREATMENT PROTOCOL - MULTIPLE MYELO
Page 156 and 157:
Post-autologous transplantation pro
Page 158 and 159:
PART II - TRANSFUSIONAL PROTOCOLS A
Page 160 and 161:
PRESERVATION AND CONSERVATION: The
Page 162 and 163:
TRANSFUSION OF RED BLOOD CELLS, PLA
Page 164 and 165:
FORMAL CONTRAINDICATIONS TO THE PLA
Page 166 and 167:
1 - TRANSFUSION OF FROZEN FRESH PLA
Page 168 and 169:
COMMUNICATION FORM OF CRYOPRECIPITA
Page 170 and 171:
Volume to be = changed (*) VOLEMIA
Page 172 and 173: HEMOTHERAPIC PROTOCOL TO FALCIFORM
Page 174 and 175: 5 - TRANSFUSIONAL CONDUCT AT THE SE
Page 176 and 177: CML - Subjects with symptoms relate
Page 178 and 179: - Aplastic anemia bearers - HIV pos
Page 180 and 181: Severe reaction: anaphylactic shock
Page 182 and 183: - Heart monitoring - Prescribe Furo
Page 184 and 185: CARES AT THE PLATELETS CONCENTRATE
Page 186 and 187: ATTACHMENT I - HEMATOLOGICAL CLINIC
Page 188 and 189: INFECTIOUS SPLENO MEGALIES IMMUNO L
Page 190 and 191: INVESTIGATION OF HEMORRHAGIC SYNDRO
Page 192 and 193: INVESTIGATION OF POLYGLOBULIAS: POL
Page 194 and 195: ATTACHMENT III - HEMATOLOGY SPECIAL
Page 196 and 197: IMMUNOPHENOTYPE PROFILE OF THE ACUT
Page 198 and 199: ATTACHMENT IV - PAIN APPROACH ROUTI
Page 200 and 201: If it is prescribed for more than 1
Page 202 and 203: HOW TO PRESCRIBE OPIOID: SPECIAL CA
Page 204 and 205: SPECIFICITIES OF EACH OPIATE (cont
Page 206 and 207: METHADONE Intravenous (*) Oral path
Page 208 and 209: Psychic Dependence or “addiction
Page 210 and 211: CROSS TOLERANCE - The subject must
Page 212 and 213: ATTACHMENT V - CHEMOTHERAPY SUBJECT
Page 214 and 215: ATTACHMENT VII - IRON CHELATION GEN
Page 216 and 217: 10. G N N - DFP DFP-100 mg/kg/day d
Page 218 and 219: ATTACHMENT VIII - SEDATION IN CHILD
Page 220 and 221: 224 NOTES _________________________
Page 224: Expresso Gráfica e Editora Ltda-me
show all

Protocols - Hemorio

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?